AIMM therapeutics B.V. was established in 2004 with the goal to develop therapeutic and prophylactic human monoclonal antibodies. AIMM’s capitalizes on a breakthrough proprietary technology to isolate human monoclonal antibodies for prevention and treatment of infectious diseases, inflammatory diseases and cancer. AIMM employs a team of 20 scientists and research technicians. We have generated a series of monoclonal antibodies specific for several pathogenic viruses and bacteria and several types of cancer. The current pipeline includes antibodies against respiratory syncytial virus, influenza virus and staphylococcus aureus, AML, Melanoma and some undisclosed cancer types. AIMM has received financing from its principal investor, the AMC and from the Life Science Fund Amsterdam.
View Top Employees from aimm therapeuticsWebsite | http://www.aimmtherapeutics.com/ |
Revenue | $5 million |
Employees | 18 (4 on RocketReach) |
Founded | 2004 |
Phone | +31 20 566 2145 |
Fax | +31 20 566 9081 |
Technologies |
JavaScript,
HTML,
Twitter
+4 more
(view full list)
|
Industry | Biotechnology, Business Services General, Drug Discovery, B cells, Pharmaceuticals, Business Services, Science and Engineering, Other Pharmaceuticals and Biotechnology, Monoclonal antibodies, Human immunology, Rabbit antibodies, Infectious diseases, Cancer |
Web Rank | 9 Million |
Keywords | Aimm Therapeutics, Aimm Therapeutics Flu Virus, Influenza, Aimm Therapeutics + Conference, Aimm Therapeutics At1412 |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular aimm therapeutics employee's phone or email?
The aimm therapeutics annual revenue was $5 million in 2024.
Willem van Oort is the Chief Operations Officer of aimm therapeutics.
4 people are employed at aimm therapeutics.
aimm therapeutics is based in Amsterdam, Noord-Holland.
The NAICS codes for aimm therapeutics are [54, 541, 5417].
The SIC codes for aimm therapeutics are [283, 28].